Cardiovascular safety of liraglutide for the treatment of type 2 diabetes

References

• Diabetes Atlas 7th edition. Brussels: International Diabetes Federation; 2015. Available from: http://www.idf.org/diabetesatlas
   Google Scholar
• Type 2 diabetes in adults: management. London (UK): National Institute of Health and Care Excellence; 2015. NG28. Available from: https://www.nice.org.uk/guidance/ng28
   Google Scholar
• Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–1596.
   PubMed Web of Science ®Google Scholar
• Garber A, Abrahamson M, Barzilay J, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine Pract. 2013;19:327–336.
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig. 2013;4:108–130.
   PubMed Web of Science ®Google Scholar
• Perry CM. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2011;71:2347–2373.
   PubMed Web of Science ®Google Scholar
• Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69:1985–2004.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S. Victoza liraglutide (rDNA origin) injection: US prescribing information; 2013. Available from: http://www.novo-pi.com/victoza.pdf
   Google Scholar
• Armstrong M, Hull D, Guo K, et al. Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebo-controlled trial. Lancet. 2014;383:S21.
   PubMed Web of Science ®Google Scholar
• Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab. 2013;15:958–962.
   PubMed Web of Science ®Google Scholar
• Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258–266.
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481.
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–278.
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care. 2009;32:84–90.
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–1230.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. Diabetologia. 2009;52:2046–2055.
   PubMed Web of Science ®Google Scholar
• Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet. 2010;375:1447–1456.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Madsen L, Jacobsen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent, but not human, thyroid C-cells causing calcitonin release and proliferation. Endocrinology. 2010;151(4):1473–1486.
   PubMed Web of Science ®Google Scholar
• Chatterjee DJ, Khutooryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol. 2009;49:1353–1362.
   PubMed Web of Science ®Google Scholar
• Russo GT, Labate AM, Giandalia A, et al. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2015;38:81–89.
   PubMed Web of Science ®Google Scholar
• Gautier JF, Martinez L, Penfornis A, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice—EVIDENCE: A prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2015;32:838–853.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: https://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf
   Google Scholar
• Seshasai SR, Kaptoge S, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause specific death. N Engl J Med. 2011;364:829–841.
   PubMed Web of Science ®Google Scholar
• Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus — mechanisms, management, and clinical considerations. Circulation. 2016;133:2459–2502.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288–2296.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab. 2014;40:176–185.
   PubMed Web of Science ®Google Scholar
• Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008–2017.
   PubMed Web of Science ®Google Scholar
• Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Department of Health and Human Services. Washington (DC): FDA/Center for Drug Evaluation; 2008. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf
   Google Scholar
• Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. London (UK): European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–1201.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet. 2009;373:2125–2135.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166:240–249.
   PubMed Web of Science ®Google Scholar
• Hirshberg B, Raz I. Impact of the US Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34(Suppl 2):S101–6.
   PubMed Web of Science ®Google Scholar
• Hirshberg B, Katz A. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective. Curr Diab Rep. 2015;15:87.
   PubMed Web of Science ®Google Scholar
• Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237–240.
   PubMed Web of Science ®Google Scholar
• Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization (MedDRA MSSO). Available from: http://www.meddramsso.com/
   Google Scholar
• FDA Briefing Document NDA 206321 Liraglutide injection, 3mg. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, FDA, Washington, USA; 2014. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413317.pdf
   Google Scholar
• Bain SC, Caterson ID, Gross JL, et al. Cardiovascular safety of liraglutide: meta-analysis of major adverse cardiovascular events across weight management and T2D development programmes. Diabetologia. 2015;58(Suppl 1):S573 abstract 1193.
   Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Van De Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus. JAMA Cardiol. 2016;2:126–135.
   Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Hirano T, Mori Y. Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypeptide, and dipeptidyl peptidase‐4 inhibitors in experimental animals. J Diabetes Investig. 2016;7(Suppl 1):80–86.
   PubMed Web of Science ®Google Scholar
• Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomized controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–1016.
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes. 2016 Dec;40(6):484–486.
   PubMed Web of Science ®Google Scholar